Boston Scientific (NYSE:BSX) Stock Gets Price Target Reduction from Leerink Partners

Boston Scientific (NYSE:BSX) had its price target decreased by Leerink Partners from $60.00 to $55.00 in a research report released on Friday.

BSX has been the subject of several other research reports. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Jefferies Financial Group reduced their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Argus reissued a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Wells Fargo & Company decreased their target price on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a research note on Wednesday, September 23rd. Finally, Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.60.

Boston Scientific Stock Up 1.0%

Shares of NYSE BSX traded up $0.42 on Friday, hitting $43.16. The company had a trading volume of 1,992,125 shares, compared to its average volume of 18,609,771. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific has a 12-month low of $41.38 and a 12-month high of $105.65. The firm has a market capitalization of $62.54 billion, a P/E ratio of 17.48, a PEG ratio of 1.03 and a beta of 0.58. The business has a 50 day moving average of $46.56 and a two-hundred day moving average of $50.52.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company’s revenue was up 7.5% on a year-over-year basis. During the same period last year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts forecast that Boston Scientific will post 3.25 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

A number of hedge funds have recently made changes to their positions in BSX. GK Wealth Management LLC bought a new stake in shares of Boston Scientific in the 3rd quarter worth about $41,000. Riversedge Advisors LLC lifted its position in shares of Boston Scientific by 83.2% during the third quarter. Riversedge Advisors LLC now owns 13,733 shares of the medical equipment provider’s stock worth $599,000 after purchasing an additional 6,237 shares during the last quarter. Wedmont Private Capital lifted its position in shares of Boston Scientific by 6.3% during the third quarter. Wedmont Private Capital now owns 27,800 shares of the medical equipment provider’s stock worth $1,213,000 after purchasing an additional 1,652 shares during the last quarter. LifeGoal Investments LLC acquired a new position in Boston Scientific in the third quarter worth about $428,000. Finally, Mn Services Vermogensbeheer B.V. grew its stake in Boston Scientific by 8.1% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 467,972 shares of the medical equipment provider’s stock worth $20,427,000 after purchasing an additional 34,959 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.